Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
ESMO 2021: Recommendations From Dr. Barbara Burtness for Head and Neck Cancer
- Written by
-
Barbara
Burtness
MD
Thursday, September 16, 2018
ePoster Display
Head and Neck Cancer
906P Simlukafusp α and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck
Presenter: Aaron Hansen
867P A phase I trial of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma
Presenter: Ari Rosenberg
890P Concordance analysis of PD-L1 CPS in different sample types of head and neck squamous cell cancer
Presenter: Stijn De Keukeleire
872P Association between event-free (EFS) and overall survival (OS) in newly diagnosed patients (pts) with locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) ineligible for surgery
Presenter: Christopher Black
883P Preliminary study of a new antibody marker anti-EBV BNLF2b in screening population in high-incidence areas of nasopharyngeal carcinoma
Presenter: Mingfang Ji
904P ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort
Presenter: Alan Ho